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Abdominal aortic aneurysms are a substantial burden on
health care in more developed countries, occurring
mostly among men older than 65 years of age. The
disorder is the thirteenth leading cause of death in the
USA.1 Although some patients have vague symptoms,
such as back pain or abdominal pain, most abdominal
aneurysms are asymptomatic until rupture, which leads
to death in 65% of patients.2 An increased awareness of
the characteristics of abdominal aortic aneurysm by ﬁrst-
contact practitioners might reduce the risk of a fatal
outcome with this disorder. Here, we review the key
aspects of this disorder, including epidemiology,
pathogenesis, diagnosis, and treatment.
Terminology
Aneurysm derives from the Greek ανευρυσµα
(aneurusma), meaning widening, and can be deﬁned as
a permanent and irreversible localised dilatation of a
vessel. Although an aneurysm occurring in any portion
of the infradiaphragmatic aorta could be termed an
abdominal aortic aneurysm, common practice restricts
this deﬁnition to an aneurysm of the infrarenal aorta.
Aneurysms involving the renal ostia (intrarenal,
suprarenal aorta) are also included under this term.
The normal diameter of the abdominal aorta varies
with age, sex, and bodyweight,3 and decreases
progressively from its entry into the abdominal cavity
to the iliac bifurcation. In elderly men, the infrarenal
abdominal aortic diameter is between 15 mm and
24 mm.4 McGregor and colleagues5 proposed the
deﬁnition of an  abdominal aortic aneurysm  as an
aorta with an infrarenal diameter greater than 30 mm.
In 1991, the Society for Vascular Surgery and the
International Society for Cardiovascular Surgery Ad
Hoc Committee on Standards in Reporting proposed
as a criterion that the infrarenal diameter should be
1·5 times the expected normal diameter.6 There is no
deﬁnite consensus on the deﬁnition of abdominal
aortic aneurysm; however, the disorder is conven-
tionally diagnosed if the aortic diameter is 30 mm or
more. This dilatation affects the three layers of the
vascular tunic; otherwise, the dilatation is called a
pseudoaneurysm. Most aneurysms are fusiform since
the whole circumference of the artery is affected,
whereas an aneurysm that includes only a part of the
circumference is termed saccular. An inﬂammatory
aneurysm is characterised by extensive perianeurysmal
and retroperitoneal ﬁbrosis and dense adhesions to
adjacent abdominal organs.
Epidemiology
The incidence of abdominal aortic aneurysms has
increased during the past two decades, due in part to
the ageing of the population, the rise in the number of
smokers, the introduction of screening programmes,
and improved diagnostic tools. Rupture of these
aneurysms causes about 8000 deaths per year in the
UK and roughly 15 000 per year in the USA.1,7 The
disorder is more common in men than in women, with
prevalence rates estimated at between 1·3% and 8·9%
in men and between 1·0% and 2·2% in women.8–12
However, since smoking is one of the most important
risk factors for abdominal aortic aneurysm13 and the
number of female smokers is rising,14 the sex ratios for
the prevalence of the disorder will probably change in
the future.10,11 Most aneurysms discovered by screening
are of small size and do not need immediate surgical
repair.15–17 However, they can become enlarged  with
time at a mean rate that is initially slow and then
increases exponentially.18 In general, the risk of
rupture increases as the diameter of the aneurysm
enlarges.14,19,20 The overall mortality rate for patients
with ruptured abdominal aortic aneurysms is between
65% and 85%,2,7 and about half of deaths attributed to
rupture occur before the patient reaches the surgical
room.21,22
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Abdominal aortic aneurysms cause 1·3% of all deaths among men aged 65–85 years in developed countries. These
aneurysms are typically asymptomatic until the catastrophic event of rupture. Repair of large or symptomatic
aneurysms by open surgery or endovascular repair is recommended, whereas repair of small abdominal aortic
aneurysms does not provide a signiﬁcant beneﬁt. Abdominal aortic aneurysm is linked to the degradation of the
elastic media of the atheromatous aorta. An inﬂammatory cell inﬁltrate, neovascularisation, and production and
activation of various proteases and cytokines contribute to the development of this disorder, although the underlying
mechanisms are unknown.  In this Seminar, we aim to provide an updated review of the pathophysiology, current
and new diagnostic procedures, assessment, and treatment of  abdominal aortic aneurysm to provide family
practitioners with a working knowledge of this disorder.
Search strategy and selection criteria
The primary source of references included MEDLINE searches
for recent literature with many keywords for both clinical and
basic research topics. We largely selected publications in the
past 5 years, but did not exclude commonly referenced and
highly regarded older publications. We also reviewed books
and review articles pertaining to abdominal aortic aneurysm.
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Aetiology and risk factors
There are many causes of aneurysmal dilatation, but few
abdominal aortic aneurysms are the direct consequence
of speciﬁc causes such as trauma, acute infection
(brucellosis, salmonellosis), chronic infection
(tuberculosis), inﬂammatory diseases (Behçet and
Takayasu disease),23,24 and connective tissue disorders
(Marfan Syndrome, Ehlers-Danlos type IV).25 Thus, most
abdominal aortic aneurysms are called non-speciﬁc.6
Moreover, because this disorder is invariably associated
with severe atherosclerotic damage of the aortic wall, it
has been traditionally regarded as a consequence of
atherosclerosis.26 This conventional view has been
increasingly challenged in recent years. Clinical and
basic research studies indicate that aneurysms arise
through pathogenic mechanisms that differ, at least in
part, from those responsible for athero-occlusive
disease.27,28 Much published work lends support to this
concept.29,30 Defawe and colleagues31 showed that two
physiological inhibitors of proteases (TIMP-2 and PAI-1)
were expressed less in abdominal aortic aneurysms than
in athero-occlusive disease, suggesting a signiﬁcant role
for protease inhibitors during the divergent evolution of
the initial atherosclerotic plaque towards either
abdominal aortic aneurysm or athero-occlusive disease.
Moreover, since not all patients with atherosclerosis
develop an abdominal aortic aneurysm, even if
atherosclerosis does have a role in the pathogenesis of
the disorder, additional factors are probably involved in
aneurysm development.
There is a strong clinical association between tobacco
smoking and aneurysm development.12,14,32,33 The
prevalence of abdominal aortic aneurysms in tobacco
smokers is more than four times that in life-long non-
smokers.12 A report that compared relative risks for
different diseases in chronic cigarette smokers showed
that the risk of developing abdominal aortic aneurysms
is three-fold greater than the risk for developing
coronary artery disease and nearly ﬁve-fold greater than
the risk for cerebrovascular disease.34 Based on these
clinical observations, chronic tobacco smoking is
probably the single most important environmental risk
factor for development and progression of aortic
aneurysms. The rate of growth of these aneurysms has
been reported to be higher in current smokers than in
non-smokers (2·83 mm per year vs 2·53 mm per year,
respectively).35 The mechanisms by which smoking
could promote aneurysm formation remain unknown
and are being investigated.36 Beside tobacco smoking,
other risk factors include male sex, age, hypertension,
chronic obstructive pulmonary disease, hyperlipidaemia,
and family history of the disorder.10–12,35,37
The familial clustering of abdominal aortic aneurysms
has drawn attention to non-environmental risk factors
for the disorder. Since the ﬁrst case report by Clifton in
1977,38 several studies have lent support to the notion
that abdominal aortic aneurysms are one of the most
common familial diseases. The frequency of the disorder
in ﬁrst-degree relatives is 15–19% compared with only
1–3% in unrelated patients.39 Familial abdominal aortic
aneurysms are more frequently found when the proband
is a female and rupture occurs more often and at a
younger age than with sporadic aneurysms.40,41 Two
research groups have attempted segregation analysis of
abdominal aortic aneurysm. Majumder and co-workers,42
in a segregation analysis based on 91 probands and
including 13 familial cases, showed that the most likely
genetic model was an autosomal locus with a recessive
inherited gene for the disorder. An analysis undertaken
in 313 pedigrees, by Verloes and colleagues,40 provided
evidence for a single autosomal dominant inheritance. A
multinational study identiﬁed 233 families with 653
affected members;39 the inheritance mode was
autosomal recessive in 72% of families and autosomal
dominant in 25% of families. Linkage between aortic
aneurysm growth and a 4G/5G polymorphism in the
plasminogen activator inhibitor (PAI-1) promoter has
been recorded.43,44 Linkage of abdominal aortic aneurysm
frequency to a locus on chromosome 19q13 has also
been reported.45 Several candidate genes are present in
this region of chromosome 19, such as LDL receptor-
related protein 3 (LRP3), which is particularly relevant
since conditional knockout mice for LRP1, another
member of this gene family, developed atherosclerosis
and arterial aneurysm.46
As discussed by Powell,47 familial clustering of
abdominal aortic aneurysms is probably not due to
chance alone. An underlying cause could be particular
genetic background, as mentioned before, but probably
in conjunction with environmental factors. In
comparison, clear evidence was reported for the
interaction between smoking and polymorphic variation
in the nitric oxide synthase gene for the development of
carotid artery disease.48 Familial clustering of abdominal
aortic aneurysms could also result from exposure to
common environmental factors, such as tobacco smoke.
Parental smoking has been suggested to underlie
familial clustering.47 Additionally, women who smoke
tend to have infants of low birthweight who have a high
risk of developing coronary diseases later in life.49
Pathophysiology
The development of abdominal aortic aneurysms is
clearly associated with alterations of the connective
tissue in the aortic wall. Elastic ﬁbres and ﬁbrillar
collagens are the main determinants of the mechanical
properties of the aorta. Elastin and associated proteins
form a network of elastic ﬁbres responsible for the
viscoelastic properties. Elastin is stabilised by cross-links
between the molecules and can be degraded by speciﬁc
proteases that display elastase activity. Elastic ﬁbres
associated with smooth muscle cells are most abundant
in the media of the aortic wall. Collagen, in polymeric
form, is also a signiﬁcant component of the media and
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the surrounding ﬁbrous adventitia. Two speciﬁc types of
ﬁbrillar collagen (types I and III) provide tensile strength
and help maintain the structural integrity of the vascular
wall. Beside elastic and collagen ﬁbres, proteoglycans are
also implicated in the organisation of the aortic wall.50
One of the most important histological features of
aneurysmal tissue is the fragmentation of the elastic
ﬁbres and a decreased concentration of elastin during
aneurysm growth until the time of rupture.51–53 The loss
of elastic ﬁbres seems to be an early step in aneurysm
formation.54 Although elastin fragmentation and medial
attenuation are the most important characteristics of the
wall of an aneurysm, the adventitial tissue, in which
collagen is predominant, is responsible for the
resistance of the aorta in the absence of medial elastin.
According to Dobrin and Mrkvicka,54 collagen
degradation is the ultimate cause of rupture. Increased
collagen turnover has been reported in abdominal aortic
aneurysms in human beings,55 suggesting the existence
of a repair process as shown in animal models.56 An
imbalance between collagen degradation and its
synthesis could create the catabolic conditions that lead
to rupture.
The alteration of elastin and collagen in the aortic wall
is dependent on production of proteases by resident
vascular wall cells (medial smooth muscle cells and
adventitial ﬁbroblasts) and by the cells of the
lymphomonocytic inﬁltrate. These inﬂammatory cells in
the media and adventitia come from the aortic blood and
from a medial neovascularisation, which characterises
abdominal aortic aneurysms.57–59 Leucocyte recruitment
into the aortic wall is promoted by elastin degradation
fragments as well as proinﬂammatory cytokines,
chemokines, and prostaglandin derivates produced by
both the resident mesenchymal cells and the
inﬂammatory cells themselves.60–63 Immunity has been
suggested to play a part in the development of
abdominal aortic aneurysm.64,65 Elastic and collagen
ﬁbres are degraded by proteolytic enzymes mostly
represented by matrix metalloproteinases (MMP) locally
activated by either other MMP or by plasmin generated
by plasminogen activators.30,31,66–79 The role of MMP and
plasmin in the development of abdominal aortic
aneurysms has been conﬁrmed in animal
models.70,76,77,80–84 The tissue inhibitors of matrix
metalloproteinases (TIMP) are also increased in the wall
of the aneurysm.69 However, the balance between
proteases and antiproteases seems to be in favour of
proteolysis.31,85,86 The importance of this imbalance in
aneurysm development is reinforced by experimental
studies in which the antiproteases are overexpressed or
genetically inactivated.87–90
Besides rarefaction of its extracellular matrix, the
elastic media also undergoes a reduction in the density
of smooth muscle cells, which is regarded as a key event
in the development of abdominal aortic aneurysms.91
Smooth muscle cells participate in vascular wall
remodelling through localised expression of various
extracellular matrix proteins as well as proteases and
their inhibitors. Additionally, smooth muscle cells have
a protective role against inﬂammation and proteolysis.92
In-vitro aortic smooth-muscle cells have been shown to
produce less monocyte chemotactic protein-1 (MCP-1), a
major inﬂammatory mediator in abdominal aortic
aneurysms, under cyclic stretching than with static
culture, which lends support to the notion of a protective
paracrine function of smooth muscle cells.93
The development of abdominal aortic aneurysms is
also associated with a mural thrombus in most patients.
By contrast with arterial occlusive diseases, blood ﬂow is
maintained in aortic aneurysms resulting in a persistent
remodelling activity of the components of the thrombus.
Evolution of aneurysmal diameter has been reported to
correlate with plasma markers of ﬁbrin formation and
degradation94 as well as the circulating complex
plasmin-2-anti-plasmin95 potentially related to
thrombus turnover. The role of an adherent thrombus in
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Figure 1: Ultrasonography of an infrarenal aortic aneurysm 
A: Sagittal section with parietal thrombus (arrow). B: Transaxial section without
thrombus. 
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aneurysmal degeneration has also been investigated.
Although the thrombus can substantially reduce
aneurysmal wall stress, its increasing thickness leads to
local hypoxia at the inner layer of the media, which can
induce increased medial neovascularisation and
inﬂammation.96 The implication of the thrombus in
aneurysmal evolution in terms of a source of proteases
has also been proposed after an initial report of an
enrichment of MMP-9 (gelatinase B) in the thrombus.68
Furthermore, Fontaine and colleagues97 have provided
evidence of polymorphonuclear neutrophils (PMN)
trapping and storing MMP-9 within the aneurysmal
thrombus. They also showed that plasminogen and its
activator (u-PA) are present in the thrombus in the
aneurysm wall, which might result in local generation of
plasmin, an activator of MMP.
Methods of diagnosis
The examination for a pulsatile mass should be done by
bimanual palpation of the supraumbilical area.
Sensitivity of abdominal palpation for detection of
abdominal aortic aneurysms increases with the diameter
of the lesion: 61% for aneurysms 3·0–3·9 cm, 69% for
those 4·0–4·9 cm, and 82% for those 5·0 cm and larger.
The palpation sensitivity also depends inversely on the
size of the abdominal waistline.98
Abdominal standard radiography can incidentally be
diagnostic, mainly in the transverse view, if calciﬁcations
are present in the aortic wall, which allows visualisation
of dilatation. However, standard radiography is not the
method of choice for the diagnosis of abdominal aortic
aneurysms. Ultrasonography is the simplest and
cheapest diagnostic procedure and can accurately
measure the size of the aorta in longitudinal as well as in
anteroposterior and transverse directions (ﬁgure 1) with
an accuracy of 3 mm.99 Ultrasonography is largely used
not only for the initial assessment and the follow-up
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Figure 2: CT images of abdominal aortic aneurysms
A: Scan slices of a dextoconvex aneurysm in a female patient admitted with diagnosis of cholecystitis. 
B: Retroperitoneal haematoma (arrow) from a ruptured aneurysm. C: Bleeding in a parietal thrombus (arrow)
observed in a symptomatic small aneurysm. D: Para-aortic ﬁbrosis associated with ureterohydronephrosis.
Figure 3: MRI of an abdominal aortic aneurysm 
A: 2D T1-weight post contrast MRI. B: Gadolinium-enhanced MRA in the same
patient showing tortuous aorta and iliac arteries.
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surveillance, but also for population screening. If the
diameter of the aneurysm is such that surgical procedure
is contemplated, CT is the next step to help determine
which treatment should be used (endovascular or open
surgery) (ﬁgure 2). Serial CT scans can be used to
visualise the proximal neck (the transition between the
normal and aneurysmal aorta), the extension to the iliac
arteries, and the patency of the visceral arteries. They can
also measure the thickness of the mural thrombus.
Venous anomalies that can be hazardous during the
access to the neck are also clearly indicated (left vena
cava, posterior left renal vein). CT can also display the
presence of blood within the thrombus (crescent sign),
which has been regarded by some groups as a predictive
marker of imminent rupture100–102 (ﬁgure 2 C). In case of
inﬂammatory aneurysm, CT allows estimation of the
thickness of the aortic wall outside of the calciﬁed
deposits and visualisation of the presence of para-aortic
fibrosis potentially associated with ureterohydronephrosis
(ﬁgure 2 D). Extravasation of contrast material is
diagnostic of aneurysm rupture. With three-dimensional
imaging, helical CT and CT angiography can provide
additional anatomical details, especially useful if
endovascular procedure is considered.103 MRI, combined
with magnetic resonance angiography (MRA) (ﬁgure 3),
is of little harm since non-nephrotoxic contrast material
(eg, gadolinium) is used, whereas conventional
arteriography uses nephrotoxic contrast material, which
can lead to renal failure and distal embolisation. Because
of the steady development of MRA and CT
angiographies, there will be hardly any place left for
conventional aortography during preoperative
assessment of the disorder. The use of conventional
aortography is mainly restricted to the placement of
endovascular devices or when a horse-shoe kidney is
diagnosed.
Clinical presentation
Unruptured abdominal aortic aneurysms
Non-ruptured aneurysms are generally asymptomatic in
most patients. They are essentially diagnosed incidentally
during extensive clinical examination, especially in
patients who complain of coronary, peripheral, or cerebro-
vascular diseases, or during population screening.22
Fleming and co-workers104 reported that population
screening in men aged 65–74 years signiﬁcantly reduces
mortality related to the disorder.
Non-ruptured aneurysms might exceptionally be
diagnosed after complications, such as distal embolisa-
tion and, even more rarely, acute thrombosis. Minor and
less speciﬁc symptoms include chronic vague abdominal
and back pain, which can result from direct pressure or
distension of adjacent structures. Recent onset of severe
lumbar pain has been deemed to indicate impending
rupture. Ureterohydronephrosis might also take place,
especially if the aneurysm is inﬂammatory or involves
the iliac bifurcation (ﬁgure 4). 
Ruptured abdominal aortic aneurysms
Rupture of abdominal aortic aneurysms is heralded by
the triad of sudden-onset pain in the mid-abdomen or
ﬂank (that may radiate into the scrotum), shock, and the
presence of a pulsatile abdominal mass. However, the
degree of shock varies according to the location and size
of the rupture and the delay before the patient is
examined. Rupture from the anterolateral wall into the
peritoneal cavity (ﬁgure 5) is usually dramatic and most
often associated with death at the scene. Most patients
with a rupture who reach the clinic alive have a rupture
of the posterolateral wall into the retroperitoneal space; a
small tear can temporarily seal the rupture and the
initial blood loss might be small. This initial event is
systematically followed within hours by a larger rupture.
This biphasic evolution emphasises the importance of
the intermediate period after the initial event, which
should be used for medical transfer and emergency
repair.
Anecdotically, the ﬁrst episode of rupture could be
deﬁnitely contained and become a chronic pulsatile
extra-aortic haematoma. Very rarely, the aneurysm
might spontaneously rupture into the duodenum
(ﬁgures 5 and 6); an incidence rate at necropsy of 0·04%
to 0·07% has been reported.105–107 More often,
aortoduodenal ﬁstula can occur after previous repair,
with an incidence rate of 0·5% to 2·3%.108 Rupture into
the vena cava can also take place with an apparent
pattern of lower extremity oedema erroneously
attributed to cavoiliac thrombophlebitis (ﬁgure 4).
However, the development of high output congestive
heart failure and the perception of continuous
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Figure 4: Ureterohydronephrosis associated with abdominal aortic aneurysm 
Ureteral stenosis (A) resulting in ureterohydronephrosis (B) in a case of inﬂammatory aneurysm with para-aortic
ﬁbrosis (C) or para-iliac (D) ﬁbrosis.
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abdominal noise is pathognomonic. The overall
prevalence of aortocaval ﬁstula is 3% to 6% of all
ruptured aortic aneurysms.109
Indications for treatment
Although surgical treatment of non-ruptured abdominal
aortic aneurysms relies on speciﬁc rare indications, such
as distal embolisation, ureteral compression, or
contained retroperitoneal haemorrhage, treatment of
intact abdominal aortic aneurysm is essentially
prophylactic and aimed at prevention of fatal rupture.
Indication for surgical treatment is deduced from the
estimated risk of rupture, the estimated risk of the
surgical procedure, and the estimated life expectancy of
the patient. Figure 7 shows a proposed management
plan for asymptomatic abdominal aortic aneurysms.
Risk of rupture
The size of the aneurysm is a universally recognised
factor to forecast rupture, and the general consensus is
that patients with a large aneurysm should undergo
surgery. The real controversy surrounds the
management of small aneurysms. A study was
undertaken in which patients with small aneurysms
(diameter between 4·0 cm and 5·5 cm) were randomly
assigned to two groups that underwent either early
elective surgery or delayed repair after the diameter of
the aneurysm had reached or exceeded 5·5 cm.110 The
results show closely similar survival curves for the two
groups of patients. A US Veterans Administration study
led to similar ﬁndings despite a lower operative mortality
(2·7% vs 5·8%) with early than with delayed repair.15 The
conclusions of these two studies were similar: rigorous
surveillance of infrarenal aortic aneurysms smaller than
5·5 cm in diameter is safe, whereas early surgery is not
associated with improved long-term survival. 
Rapid expansion of the aortic diameters preceding
ﬁssuration and rupture has been observed in abdominal
aortic aneurysms independently of their initial size,18,20
which suggests that the size of the aneurysm, whatever
its practical signiﬁcance, is probably not the sole useful
determinant for risk of rupture. Active investigations
have been and still are being done to identify markers
other than size that would predict a risk of rupture. A
possible candidate is the level of serum MMP-9, which
has been directly implicated in the proteolytic
degradation of the extracellular matrix of the aortic
wall.68 The amount of circulating MMP-9 has not only
been reported to be signiﬁcantly higher in patients with
abdominal aortic aneurysm,111 but has also been
signiﬁcantly associated with the size and expansion rate
of these aneurysms.112 Another factor that has been
investigated as a potential serum marker is the reduced
level of 1-antitrypsin (1-AT) since it is the most
abundant serum inhibitor of proteases. However, the
importance of this marker for the prognosis of
abdominal aortic aneurysms has not been deﬁned
because of contradictory ﬁndings.113
Family history represents a risk factor for  aneurysm
rupture. A study of 313 pedigrees showed a four-fold
higher rate of rupture in familial cases than in sporadic
cases.40 Additionally, a signiﬁcantly earlier age at rupture
(65 years vs 75 years) was also reported in these familial
cases. Another potential risk factor  for rupture could be






Figure 5: Different possible sites of rupture of an abdominal aortic aneurysm
1: Anterolateral free rupture in the abdominal cavity. 2: Retroperitoneal rupture.
3: Rupture of retroperitoneal sac. 4: Rupture into the duodenum. 5: Rupture
into the inferior vena cava.
Figure 6: Rupture of an abdominal aortic aneurysm in the duodenum 
CT displaying a known large aneurysm leaking into the duodenum (A, arrow), and presenting an air bubble in the
parietal thrombus, which is a sign of aorta enteric ﬁstula (B, arrow). The 92-year-old patient and her family had
refused any intervention. 
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related to the sex of the patient. A report from the UK
Small Aneurysm Trial has shown that the risk of rupture
in women was four-times higher than in men.16
Preliminary data obtained by PET imaging of
abdominal aortic aneurysms have shown focal uptake of
18-ﬂuorodeoxyglucose (18F-FDG) within the aneurysm
wall in patients with either large, rapidly expanding, or
painful aneurysms (ﬁgure 8).114 The uptake of 18F-FDG is
regarded as a functional image of the inﬂammatory
inﬁltrate and thus as a potential non-invasive technique
to identify unstable aneurysms that are prone to rupture. 
Risk of elective aneurysm repair
Reported mortality rate related to elective aneurysm
repair varies among hospitals and surgeons.115 Mean
30-day mortality rate has been reported at between 1·1%
and 7·0%.116–121 Between 1998 and 2003, 453 patients were
admitted to the University Hospital of Liège, Belgium,
for elective repair of an abdominal aortic aneurysm (397
by open surgery and 56 by endovascular repair); the
overall 30-day mortality, regardless of the risk factors,
after open surgery and endovascular repair was 2·7%
and 1·8%, respectively. Most deaths resulting from the
repair occurred in the so-called high-risk patients. Factors
of increased operative risk are renal failure, chronic
obstructive pulmonary disease, and, most importantly,
myocardial ischaemia. If these patients are excluded, 30-
day mortality rate of elective repair should be expected to
be as low as 2% in most hospitals.121–123
Several reports have shown the high incidence
(between 40% and 60%) of coronary artery disease in
patients with abdominal aortic aneurysm, which could
be explained by common risk factors (eg, tobacco
smoking and hypertension).124–127 Complications related
to coronary artery disease are the main cause of the
operative mortality of aneurysm surgery.126,128–131
However, the beneﬁt of coronary artery revascularisation
before surgery remains controversial. Simultaneous
aneurysm repair and coronary artery revascularisation
have been recommended in selected patients scheduled
for elective or urgent repair.132–134 However, a large
randomised study did not show any signiﬁcant
difference in the long-term outcome when coronary-
artery revascularisation was undertaken before elective
surgery.135 The investigators therefore suggested the
restriction of preoperative coronary revascularisation to
patients with unstable cardiac symptoms. As yet, there is
no consensus on the optimum strategy for preoperative
cardiac management in patients scheduled for major
elective vascular surgery.136,137
As far as emergency repair for ruptured abdominal
aortic aneurysms is concerned, mortality depends on the
haemodynamic status of the patient at the time of
surgery. By contrast with the progress in elective repair
mortality, no improvement in operative mortality of
ruptured aneurysms has been reported during the past
decades, remaining as high as 30–70%.2,22 If the
mortalities occurring at the scene of rupture, during
transfer, shortly after admission to the emergency
department, and during surgery are combined, then
only 18% of patients with ruptured aortic aneurysms
survive.138 Prance and co-workers138 suggested ﬁve
preoperative risk factors to predict the mortality rate of
ruptured abdominal aortic aneurysms: (1) age older than
76 years; (2) creatinine higher than 190 mol/L; (3)
haemoglobin below 9g/dL; (4) loss of consciousness;
and (5) ECG evidence of ischaemia. In their study, the
mortality rate was 100% when the patient had three or
more risk factors and decreased to 48%, 28%, and 18%




During open surgical treatment, the abdomen is entered
either through a long midline or a wide transverse
incision. A retroperitoneal approach has been
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Figure 7: Proposed management of an asymptomatic abdominal aortic aneurysm
Figure 8: PETof an abdominal aortic aneurysm 
Coronal section showing 18F-FDG uptake in the wall of an aneurysm 7 days before
rupture.
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recommended in patients with chronic obstructive
pulmonary disease. Disadvantages of this approach
include: ﬁrst that the intraperitoneal content cannot be
inspected; and second, access to the right iliac artery can
frequently be difﬁcult, especially if there is a large right
iliac aneurysm. Once the abdominal cavity is opened, the
neck of the aneurysm needs to be identiﬁed to control it.
In the cases of a suprarenal or intrarenal neck, a clamp
above the renal arteries might be needed brieﬂy. The
iliac arteries are controlled in much the same way. The
inferior mesenteric artery is tied close to the aortic wall
to keep it collateral to the superior mesenteric artery; in
some instances, encircling the inferior mesenteric artery
with a rubber to reimplant it on the aortic prosthesis via
a Carrell patch could be wise to maintain direct ﬂow for
sigmoid and rectum.
The vascular graft is a knitted synthetic textile sealed
with collagen or albumin. The upper anastomosis is of
the end-to-end type and the distal anastomosis is located
on the aortic bifurcation, the iliac bifurcations, or the
common femoral arteries depending on the extent of
aneurysmal transformation and the patency of the
external iliac arteries. Care is taken to preserve at least
one internal iliac artery and to detect perioperatively a
potential left colonic-ischaemia. In sexually active male
patients, the recommendation is not to dissect the lateral
left aortic wall and the common left iliac artery.
Whenever possible, iliac anastomosis should be the
preferred choice instead of common femoral
anastomosis because anastomosis in the groin is more
prone to infection. Speciﬁc morbidities linked to surgery
are left colon ischaemia and renal failure (eventually due
to thrombo-embolic events in renal arteries).
Postoperative paraplegia, a huge concern with thoraco-
abdominal surgery, is infrequent with abdominal aortic
aneurysm surgery. The incidence of paraplegia after
endovascular repair or open surgery has been reported
to be 0·21%139 and 0·25–0·9%,140,141 respectively. 
Since the very beginning of surgery for abdominal
aortic aneurysms, survival after successful elective
aneurysm repair has been reported to be  less than the
survival of the matched population for age and sex;
5-year survival after abdominal aortic aneurysm repair
was about 70%, whereas the expected survival of a
matched population was close to 80%.131
Coggia and co-workers142 showed, in a preliminary
study, the feasibility of repair by total laparoscopic
surgery. Even if this technique is minimally invasive and
reduces surgical trauma, more experience and further
assessment are needed to ensure that the real beneﬁt of
this technique is realised compared with open repair.
Endovascular repair 
Introduced by Parodi in 1991,143 endovascular repair
consists basically of the placement of a graft across the
aneurysm and the ﬁxation to the normal aortic and iliac
wall with stents at both ends. The aortomonoiliac
approach consists of the insertion of a stentgraft, which
is a tube of conventional graft fabric containing at least
two stents. The delivery system consists of a sheath with
some type of haemostatic mechanism and an obturator
for sheath installation and stentgraft extrusion. Many CT
angiogram-derived data are necessary to choose the best-
adapted device for the patient. The endograft is
composed of fabric and metal stents and comes loaded
in a delivery system. Under ﬂuoroscopic guidance, this
introducer system is fed through the iliac arteries by
means of catheters and guidewires until the endograft is
positioned correctly at the top and bottom of the
aneurysmal segment. Removal of the introducer system
allows the ﬁxing devices to attach to the aortic wall and
hold the graft ﬁrmly in place, excluding blood ﬂow from
the aneurysm sac and removing pressure from the
aneurysm wall. Excellent results are characterised by a
perfectly canalised blood ﬂow and later by a completely
retracted aneurysm wall around the endograft (ﬁgure 9).
Occasionally, an abdominal aortic aneurysm might
rupture, despite the presence of the endograft, if there is
still pressure in the aneurysmal sac via endoleaks
(ﬁgure 9). Some 40–80% of abdominal aortic aneurysms
could be amenable to endovascular grafting. However,
morphological contraindications for endovascular repair
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Figure 9: Potential issues of endovascular aneurysm repair
A: Rupture of an abdominal aortic aneurysm 2 years after endovascular repair. B and C: CT in another patient showing the normalisation of the diameter of an
aneurysm 6 years after endovascular repair.
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are diversely proposed in published work. The most
accepted contraindication is a proximal neck either
shorter than 15 mm or absent. 
Two randomised trials that compared conventional
and endovascular repair showed a lower operative
mortality rate for endovascular repair and less frequent
complications than with conventional techniques.144,145
However, as discussed by Lederle,146 the question “Is
endovascular repair preferable to open repair?” cannot
be answered yet since there has been no long-term
follow-up to determine whether the early promise of
endovascular repair is sustained. Two large European
registries have reported a failure rate for endovascular
repair of 3% per year (1% by rupture and 2% by a
required conversion to open repair),147–149 versus a failure
rate of 0·3% for open repair.15,150,151 Long-term results
after endovascular repair have also been reported to be
worse for large aneurysms, which are the most in need
of repair. Ouriel and colleagues152 noted that 2 years after
endovascular repair, 6·1% of patients with an
abdominal aortic aneurysm larger than 5·5 cm died
from aneurysm-related causes and 8·2% needed open
conversion.  Additionally, a 4-year postoperative rupture
rate was reported to reach 10% for large abdominal
aortic aneurysms (diameter 6·5 cm).153
Non-invasive prevention of growth and rupture
Patients with an abdominal aortic aneurysm are asked to
stop smoking tobacco completely to allow a reduction of
the growth rate of the aneurysm.35 The central role of
MMP in aneurysm development and rupture has led to
research interest in the pharmacologic inhibitors of
these proteases. Tetracyclines provide a potentially
effective treatment. Doxycycline, a synthetic tetracycline
derivative, was shown to prevent MMP-mediated
aneurysmal growth in animal models.154 Moreover,
ﬁndings from a clinical study suggested that doxycycline
treatment prevents aneurysm growth in human
beings.155 The use of synthetic inhibitors of MMP
activity, such as batimastat (BB-94), has also been shown
to suppress the expansion of experimental abdominal
aortic aneurysms.156,157 However, Defawe and
colleagues158 recently showed that MMP can alter matrix
remodelling independently of their proteolytic function,
which suggests that the role of MMP might be more
complex than mediation of a degradation process.
Another attractive option of aneurysmal pharmaco-
therapy is to target the inﬂammatory response and
interfere with the MMP pathway. Non-steroidal anti-
inﬂammatory drugs, such as indometacin, are known to
prevent development of abdominal aortic aneurysms in
animal models.159 In the past decade, various substances
have been proposed for the treatment of asymptomatic
abdominal aortic aneurysms. The use of -blocking
agents (eg, propranolol) seems to reduce the growth rate
of large (5 cm) aneurysms and even to lessen the size
of experimental aneurysms.160,161 However, a randomised
trial reported that propranolol does not have a signiﬁcant
effect on the growth rate of small aneurysms.162 Statins
(hydroxymethylglutaryl coenzyme A reductase
inhibitors), besides their cholesterol lowering effects,
reduce the expression of various inﬂammatory
molecules, including MMP.163 The addition of
cerivastatin to tissue organ cultures of abdominal aortic
aneurysms has been shown to down-regulate the
production of MMP-9, which suggests that members of
the statins family could prevent elastolysis in patients
with this disorder.164 Long-term statin use in patients
who underwent successful surgery was also associated
with reduced mortality.165 Several innovative
experimental studies have shown the potential of cell
therapies (eg, to seed cells overexpressing antiproteases
in aneurysmal walls) for prevention of aneurysmal
progression and rupture in animal models.92,166,167
Conclusion
The past ﬁve decades have been marked by continuing
progress in diagnosis, management, timing of
interventional treatments, and assessment of endo-
vascular repair versus conventional surgery. Hopefully,
the upcoming decades will provide preventive treatments
that can be applied to selected groups of individuals
identiﬁed as high risk for abdominal aortic aneurysm by
genomic or imaging technology, or both. The ﬁrst goal in
abdominal aortic aneurysm history was the prevention of
rupture; the next aim will be the prevention of abdominal
aortic aneurysm growth.
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